Leishmaniasis Market

Market Overview:

The 7 major leishmaniasis markets are expected to exhibit a CAGR of 6.38% during 2024-2034.

The leishmaniasis market has been comprehensively analyzed in IMARC's new report titled "Leishmaniasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leishmaniasis refers to a vector-borne disease caused by parasites of the Leishmania genus. It is transmitted to humans and animals through the bites of infected female sandflies. There are three primary forms of this ailment: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis is the most common type, and it primarily affects the skin, causing ulcers, sores, or nodules at the site of the sandfly bite. Mucocutaneous leishmaniasis disrupts the skin and mucous membranes of the nose, mouth, and throat, leading to difficulties in breathing, eating, and speaking. Visceral leishmaniasis is the most severe or life-threatening form of the illness, affecting multiple organs, like the spleen and liver. Various symptoms of this disease include prolonged fever, weight loss, anemia, etc. The diagnosis of the condition is typically made through the patient's medical history, underlying indications, and physical analysis. Numerous other laboratory tests, such as microscopic examination of tissue samples, culture of the protozoa, detection of the parasite's DNA using molecular techniques, etc., are also utilized to confirm a diagnosis.

The rising prevalence of poor sanitation and inadequate housing conditions that can contribute to the proliferation of sandflies and increase the likelihood of human exposure to infected bites is primarily driving the leishmaniasis market. Moreover, the escalating cases of weakened immune systems, which impair T cell function and hinder the body's ability to eliminate parasites, are also bolstering the market growth. In addition to this, the widespread adoption of effective drugs, such as sodium stibogluconate and meglumine antimoniate, since they work by inhibiting the mitochondrial function of unhealthy organisms and preventing disease progression, is acting as another significant growth-inducing factor. Furthermore, the inflating application of intravenous liposomal amphotericin B therapy, owing to its numerous benefits, like improved drug delivery to the target tissues and decreased toxicity to organs, is also creating a positive outlook for the market. Additionally, the emerging popularity of combination treatments involving cytokines and immunomodulators to potentially reduce the risk of drug resistance development, thereby enhancing parasite control, is expected to drive the leishmaniasis market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the leishmaniasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for leishmaniasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leishmaniasis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the leishmaniasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the leishmaniasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current leishmaniasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the leishmaniasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the leishmaniasis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the leishmaniasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of leishmaniasis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of leishmaniasis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of leishmaniasis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with leishmaniasis across the seven major markets?
• What is the size of the leishmaniasis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of leishmaniasis?
• What will be the growth rate of patients across the seven major markets?
   

Leishmaniasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for leishmaniasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leishmaniasis market?
• What are the key regulatory events related to the leishmaniasis market?
• What is the structure of clinical trial landscape by status related to the leishmaniasis market?
• What is the structure of clinical trial landscape by phase related to the leishmaniasis market?
• What is the structure of clinical trial landscape by route of administration related to the leishmaniasis market?